百日咳疫苗与免疫策略研究进展

doi:10.12183/j.scjpm.2024.0683

摘要/Abstract

摘要： 百日咳为百日咳鲍特菌（Bacillus pertussis）感染而引起的急性呼吸道传染病。由于百日咳疫苗不能产生持久的免疫保护,近年来部分百日咳疫苗高覆盖率的国家出现了“百日咳再现”现象,发病率呈上升趋势。本研究将介绍国内外百日咳疫苗的发展历程、种类与效果,并对百日咳的免疫策略进行概述。

关键词: 百日咳, 疫苗, 种类, 效果, 免疫策略

中图分类号:

R186

林伟照, 钱姿霞, 赵卫, 孙九峰. 百日咳疫苗与免疫策略研究进展[J]. 华南预防医学, 2024, 50(8): 683-685.

[1] 中华预防医学会.中国百日咳行动计划专家共识[J].中国疫苗和免疫,2021,27(3):317-327.
[2] 潘殊男,盛玉博.中国百日咳疫苗的现状及研发趋势初探[J].微生物学免疫学进展,2012,40(5):72-77.
[3] Lambert LC.Pertussis vaccine trials in the 1990s[J].J Infect Dis,2014,209(Sup 1):S4-S9.
[4] Decker MD,Edwards KM.Pertussis (whooping cough)[J].J Infect Dis,2021,224(Sup 4):S310-S320.
[5] 王华庆,安志杰,尹遵栋.国家免疫规划七种针对传染病70年防控成就回顾[J].中国疫苗和免疫,2019,25(4):359-367.
[6] 骆鹏,马霄.百日咳和百日咳疫苗的现状与挑战[J].中国疫苗和免疫,2019,25(3):334-339.
[7] 唐旻瑶. 青少年及成人用百白破疫苗在百日咳疾病预防中的应用[J].微生物学免疫学进展,2019,47(6):66-69.
[8] 胡业勤,段凯,李新国,等.组分无细胞百日咳疫苗纯化新工艺的建立[J].中国新药杂志,2018,27(21):2498-2504.
[9] Sheridan SL,Frith K,Snelling TL,et al.Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine:Recent epidemiology[J].Expert Rev Vaccines,2014,13(9):1081-1106.
[10] Gilberto S,Gerardo L,Cesar M,et al.Pertussis in Mexico from 2000 to 2019:A real-world study of incidence,vaccination coverage,and vaccine effectiveness[J]. Vaccine,2023,41(41):6105-6111.
[11] Mack I,Erlanger T,Lang P,et al.Dose-dependent effectiveness of acellular pertussis vaccine in infants:A population-based case-control study[J].Vaccine,2020,38(6):1444-1449.
[12] Belchior E,Guillot S,Poujol I,et al.Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis,France,2013[J].Med Mal Infect,2020,50(7):617-619.
[13] Caulfield AD,Callender M,Harvill ET.Generating enhanced mucosal immunity against Bordetella pertussis:Current challenges and new directions[J].Front Immunol,2023,14:1126107.
[14] Luis S,Camille L.The role of mucosal immunity in pertussis[J].Front Immunol,2018,9:3068.
[15] Keech C,Miller VE,Rizzardi B,et al.Immunogenicity and safety of BPZE1,an intranasal live attenuated pertussis vaccine,versus tetanus-diphtheria-acellular pertussis vaccine:A randomised,double-blind,phase 2b trial[J].Lancet,2023,401(10379):843-855.
[16] 世界卫生组织.免疫覆盖[EB/OL].(2023-07-18)[2024-02-20]. https://www.who.int/zh/news-room/fact-sheets/detail/immunization-coverage.
[17] WHO.Pertussis vaccines:WHO position paper,August 2015-Recommendations[J]. Vaccine,2016,34(12):1423-1425.
[18] Thierry-Carstensen B,Jordan K,Uhlving HH,et al.A randomized,double-blind,non-inferiority clinical trial on the safety and immunogenicity of a tetanus,diphtheria and monocomponent acellular pertussis (Tdap) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults[J].Vaccine,2012,30(37):5464-5471.
[19] Pingali C,Yankey D,Elam-Evans LD,et al.National,regional,state,and selected local area vaccination coverage among adolescents aged 13-17 Years-United States,2020[J]. MMWR Morb Mortal Wkly Rep,2021,70(35):1184-1190.
[20] Suryadevara M,Domachowske JB.Prevention of pertussis through adult vaccination[J]. Hum Vaccin Immunother,2015,11(7):1744-1747.
[21] Venkatesan P.US approval of Tdap vaccine specifically in pregnancy[J].Lancet Infect Dis,2022,22(12):1671.
[22] Razzaghi H,Kahn EK,Black LC,et al.Influenza and Tdap vaccination coverage among pregnant women-United States,April 2020[J].MMWR,2020,69(39):1391-1397.
[23] Ditosto JD,Weiss RE,Yee LM,et al.Association of Tdap vaccine guidelines with vaccine uptake during pregnancy[J].PLoS One,2021,16(7):e0254863.
[24] Murthy N,Wodi PA,McNally VV,et al.Advisory Committee on Immunization Practices Recommended Immunization Schedule for adults aged 19 years or older-United States,2024[J].MMWR,2024,73(1):11-15.
[25] Plotkin S.Plotkin's vaccines[M].Philadelphia:Elsevier,2018:729-730.
[26] Nicola V,Giusy V,Maria A,et al.Multidimensional frailty and vaccinations in older people:A cross-sectional study[J].Vaccines,2022,10(4):555.
[27] Dyda A,McIntyre P,Karki S,et al.Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program[J].Vaccine,2018,36(29):4157-4160.
[28] O’Halloran CA,Lu PJ,Meyer AS,et al.Tdap vaccination among healthcare personnel-21 states,2013[J].Am J Prev Med,2018,54(1):119-123.
[29] Barbosa SRC,Yin LW,Isabel MMD,et al.Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate:A cross-sectional serological study[J].Vaccine,2023,41(39):5769-5774.
[30] 国家卫生健康委员会.国家免疫规划疫苗儿童免疫程序及说明(2021年版)[J].中国病毒病杂志,2021,11(4):241-245.

百日咳疫苗与免疫策略研究进展

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	吴跃千, 田亚锋, 唐慧, 常义坤, 陈津伟, 李俊熹, 杜志成. 登革热蚊媒控制、疫苗与诊治的研究进展[J]. 华南预防医学, 2024, 50(8): 686-690.
[2]	庄春燕, 李武, 陈婉宜, 谭惠玲. 深圳市龙岗区居民新型冠状病毒疫苗犹豫现状及影响因素研究[J]. 华南预防医学, 2024, 50(8): 728-731.
[3]	熊灿, 梁晓峰, 孙九峰. 疫苗循证研究进展[J]. 华南预防医学, 2024, 50(7): 591-593.
[4]	黄芳芳, 孙亚兵, 魏俊妮. 阳泉市人群接种新冠疫苗疑似预防接种异常反应监测分析[J]. 华南预防医学, 2024, 50(6): 556-559.
[5]	廖俊蕾, 甘立勤, 赖妙儿, 何志海. 深圳市龙岗区托幼机构物体表面消毒效果评价[J]. 华南预防医学, 2024, 50(5): 462-464.
[6]	钱姿霞, 孙九峰. 百日咳的流行、发病与治疗进展[J]. 华南预防医学, 2024, 50(4): 296-298.
[7]	边举元, 张国珍. 基于信息-动机-行为技巧模型的新疆大学生HPV疫苗接种意愿影响因素研究[J]. 华南预防医学, 2024, 50(4): 304-308.
[8]	文华, 周文旭, 周哲人, 翁改志, 苗金钰, 朱占芳, 杨浩杰, 刘飞, 白苗, 杨燕燕, 于敏, 路军梅. 西安地区成年居民出血热认知研究及疫苗接种意愿分析[J]. 华南预防医学, 2024, 50(4): 333-336.
[9]	刘灿, 陈洪升, 陈子慧, 蒋宇明, 谭彦君, 黄盼盼, 黄琼. 《湿米粉生产和经营卫生规范》（DBS 44/017–2021）执行现况分析[J]. 华南预防医学, 2024, 50(3): 263-266.
[10]	周然, 雷子龙, 邹显东, 马晓江, 曾娟, 董辉. 基于中断时间序列模型对河北省扩大免疫规划前后风疹防控效果评价分析[J]. 华南预防医学, 2024, 50(2): 99-103.
[11]	李夏菲, 杨帆, 樊舒曼. 运城市育龄女性人乳头瘤病毒认知度及HPV疫苗接种意愿调查[J]. 华南预防医学, 2023, 49(9): 1202-1204.
[12]	谢冰艳, 潘佑记, 陈玉格, 许雷. 连云港市2012—2021年出生队列儿童EV 71型疫苗接种情况分析[J]. 华南预防医学, 2023, 49(8): 981-985.
[13]	徐娟, 巢婷婷, 肖佳奇, 刘娜, 王文瑜, 栾琳. 新型冠状病毒感染疫情前后苏州市≥60岁人群流感疫苗接种情况分析[J]. 华南预防医学, 2023, 49(7): 936-939.
[14]	林青梅, 黎敏, 俞凯, 罗伟东, 谢俊兴, 郑寒龙, 马丽明. 信息系统支持下新消除方案阻断乙肝母婴传播的生态学研究[J]. 华南预防医学, 2023, 49(4): 452-455.
[15]	黄园嫣, 廖玉宜, 刘超群, 张吉凯. 国产重组乙型肝炎疫苗（酿酒酵母）的安全性、免疫效果及社会效益研究进展[J]. 华南预防医学, 2023, 49(3): 263-267.